Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

As you might know, Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) just kicked off its latest second-quarter results ...

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Highlights,XTX Topco Ltd significantly increased its position in Amicus Therapeutics during the first quarter,Shares of ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $24.4 million in its second quarter. On a per-share basis, the Princeton, New Jersey-based ...

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July ...

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Amicus Therapeutics (($FOLD)) has held its Q2 earnings call. Read on for the main highlights of the call. Amicus Therapeutics’ recent earnings ...

Investing.com - Morgan Stanley has upgraded Amicus Therapeutics (NASDAQ:FOLD) from Equalweight to Overweight with a price target of $12.00, citing the company’s strong intellectual property ...